Literature DB >> 30591446

Culturing the Human Natural Killer Cell Line NK-92 in Interleukin-2 and Interleukin-15 - Implications for Clinical Trials.

Heidi Törnroos1, Henry Hägerstrand1, Christer Lindqvist2.   

Abstract

BACKGROUND/AIM: The human natural killer cell line NK-92 is increasingly being used in adoptive cell immunotherapies, either in vitro or in animal models transduced with different chimeric antigen receptor (CAR) constructs. Herein, NK-92 cells were analyzed with respect to their proliferation and cytotoxicity, in the presence of interleukin-2 (IL-2) and interleukin-15 (IL-15).
MATERIALS AND METHODS: A time-resolved fluorometric assay (TDA-labeled K562 target cells) was used for measuring the cytotoxic activity of NK-92 cells treated with IL-2, IL-4, IL-7 and/or IL-15. Their proliferation, in the presence of these common cytokine receptor γ chain (γc)-dependent cytokines, was measured by traditional tritiated thymidine ([3H]-TdR) incorporation.
RESULTS: IL-2 and IL-15, but not IL-4 or IL-7, were able to induce a dose-dependent proliferation of NK-92 cells. IL-15 was, depending on the dose and culture time, up to 10 times more potent compared to corresponding concentrations of IL-2, whereas their combination could potentiate the NK-activity almost equally well. No synergistic effects could be noticed with respect to the cytotoxicity and the proliferation of these cells.
CONCLUSION: Data presented here indicate that of the common gamma chain receptor-dependent cytokines tested here, IL-15 alone is able to cultivate and trigger NK-92 cells to such an extent so that they can be used for immune-based cancer therapies. Implications with respect to CAR-transduced NK-92 cells are also discussed. Copyright
© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Common gamma chain (γc); NK-92; interleukin-15; interleukin-2; natural killer cell

Mesh:

Substances:

Year:  2019        PMID: 30591446     DOI: 10.21873/anticanres.13085

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

1.  Generation and validation of CRISPR-engineered human natural killer cell lines for research and therapeutic applications.

Authors:  Anil Kumar; Sung June Lee; Qiao Liu; Anthony K N Chan; Sheela Pangeni Pokharel; Jianhua Yu; Chun-Wei Chen; Srividya Swaminathan
Journal:  STAR Protoc       Date:  2021-10-21

2.  Clinical Value of Cytokine Assay in Diagnosis and Severity Assessment of Lung Cancer.

Authors:  Jin Ma; Shumin Zhu; Zining Liu; Yafei Mao; Xinyuan Li; Lili Dai; Xiaojie Zhao; Congzhen Wei; Jinfeng Liu; Yulan Geng
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-09       Impact factor: 2.650

Review 3.  NKp30 - A prospective target for new cancer immunotherapy strategies.

Authors:  Pedro F Pinheiro; Gonçalo C Justino; M Matilde Marques
Journal:  Br J Pharmacol       Date:  2020-08-26       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.